4 recruiting, 2 active not recruiting, 1 completed, 1 not yet recruiting. 9 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 4, Active not recruiting 1, Completed 1, Not yet recruiting 1, Suspended 1, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative: new trials by email Literature Review of B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative trials Research Report on B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 53 | 2025-10-10 | 2026-10-13 |
| Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia Blinatumomab, Induction Chemotherapy, Hyper-CVAD - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 101 | 2025-04-01 | 2026-05-04 |
| Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 2 | Active not recruiting | University of Washington | 32 | 2023-03-27 | 2026-05-11 |
| Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2019-05-08 | 2026-10-26 |
| Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dexamethasone - Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2018-03-28 | 2026-07-30 |
| Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2017-04-06 | 2025-03-03 |
| Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 488 | 2014-05-19 | 2026-09-21 |
| Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia Blinatumomab, Cyclophosphamide, Cytarabine - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 276 | 2011-08-26 | 2026-07-15 |
Burkitt Lymphoma (10) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia, Biphenotypic, Acute (1)
DNA Virus Infections (10) · Epstein-Barr Virus Infections (10) · Hemic and Lymphatic Diseases (10) · Herpesviridae Infections (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Infections (10) · Lymphatic Diseases (10) · Lymphoma (10) · Lymphoma, B-Cell (10) · Lymphoma, Non-Hodgkin (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Tumor Virus Infections (10)
Cyclophosphamide (7) · Vincristine (7) · Rituximab (6) · CT-P10 (5) · Cytarabine (5) · Dexamethasone (5) · Mercaptopurine (5) · Methotrexate (5) · Prednisone (5) · Specimen Handling (5) · blinatumomab (5) · Biopsy (4) · Calcium Dobesilate (4) · Doxorubicin (4) · Spinal Puncture (4)
National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (2) · University of Washington (2) · City of Hope Medical Center (1) · SWOG Cancer Research Network (1) · The First Affiliated Hospital of Soochow University (1)
United States (8) · Puerto Rico (2) · Canada (1) · China (1) · Israel (1)
Ibrahim Aldoss (2) · Aref Al-Kali (1) · Elias Jabbour (1) · Elias Jabbour, MD (1) · Mark R Litzow (1) · Matthew J Wieduwilt (1) · Ryan D. Cassaday (1) · Ryan D. Cassaday, MD (1) · Suning Chen (1)
PMID 35622074, PMID 41671463, PMID 28859185, PMID 29352703, PMID 32589970, PMID 37131217, PMID 37187201, PMID 37960985, PMID 38551807, PMID 39047240, PMID 41026957, PMID 42832396
N01CM00099 (1), P30CA016672 (1), P30CA033572 (1), U10CA021115 (1), U10CA180820 (1), U10CA180821 (1), U10CA180888 (1), U24CA196172 (1), UM1CA186686 (1)